ONYX Pharmaceuticals (ONXX)
ONYX Pharmaceuticals Market Cap: 2.933B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ONXX Market Cap Rankings
| Overall | 78th percentile | 1023 of 4664 |
| Sector | 85th percentile | 77 of 527 in Healthcare |
| Industry | 92nd percentile | 13 of 164 in Biotechnology |
ONXX Market Cap Range, Past 5 Years
| Minimum | 1.352B | Jun 2010 |
| Maximum | 3.065B | Dec 2007 |
| Average | 2.050B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these ONXX related companies
ONXX News
Drug Stocks In The Spotlight At ASCO Conference. $JNJ $CELG $ONXX $RHHBY $PFE http://stks.co/42e8
about 16 hours ago by abubnic
about 16 hours ago by abubnic
Conditions of Growth, Economic Analysis - Research Report on Qiagen NV and Onyx Pharmaceuticals, Inc.
May 30, 9:00AM Marketwire
May 30, 9:00AM Marketwire
Good article in NCI Cancer Bulletin explaining mechanism of Sorafenib http://stks.co/41UQ $ONXX
about 2 days ago by illinijill
about 2 days ago by illinijill
RT @ianestepan $CLDX if this data was from $BMY,$ONXX,$MDVN,$DNA or $PFE - people would be soooooo excited....
about 8 days ago by N0M0NEY_N0H0NEY
about 8 days ago by N0M0NEY_N0H0NEY
Baird Reiterates a 'Neutral' on Onyx Pharmaceuticals (ONXX); Nexavar Miss Not Real Issue; Kyprolis Remains Focus
May 22, 9:46AM Street Insider
May 22, 9:46AM Street Insider
Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
May 22, 6:46AM Street Insider
May 22, 6:46AM Street Insider
RT @adamfeuerstein Outlooks for $PFE $ARNA $ONXX -- Weekly #biotech and pharma thoughts from @natesadeghi --> http://stks.co/3uoM
about 10 days ago by AceOfSpades
about 10 days ago by AceOfSpades
$ONXX Mentioned more than normal on StockTwits - Currently at 5 x average daily social activity
about 14 days ago by TradeIdeasQuant
about 14 days ago by TradeIdeasQuant
$ONXX - five sessions/abstracts on carfilzomib at June ASCO Conference. http://stks.co/3sG1
about 14 days ago by abubnic
about 14 days ago by abubnic
http://stks.co/3s0J Premarket gainer $SHLD (8%), $VELT(7%), $ONXX(6%), $CTRP, $A, $WMT, $JCP
about 14 days ago by freefdawatchlistcom
about 14 days ago by freefdawatchlistcom
Long swingplays for today : $CRI $CNW $ONXX $WFM $$ $STUDY - http://stks.co/3rtz
about 14 days ago by ChartMill
about 14 days ago by ChartMill
RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech
about 15 days ago by WolfsBiotechs
about 15 days ago by WolfsBiotechs
$ONXX http://stks.co/3nAw watch list stock now 77% of full day day volume - break working well so far
about 20 days ago by StockTiger
about 20 days ago by StockTiger
Listen to $ONXX Onyx Pharmaceuticals at Deutsche Bank AG Health Care Conference - live at 09:20 AM, ondemand after - http://stks.co/3hMo
about 24 days ago by earningscast
about 24 days ago by earningscast
Loads of charts - stocks - Futures - Gold - Oil - Weekend Newsletter http://stks.co/3hLa $EQR $ERY $IN $ONXX $STRI $ZUMZ
about 24 days ago by StockTiger
about 24 days ago by StockTiger
$onxx even those love is completely out of the company Aug1 including transition period, why so many protection clauses
about 25 days ago by rabmanducky
about 25 days ago by rabmanducky
$ONXX http://stks.co/3gzh On bounce from support or on Break out over downtrend line
about 25 days ago by StockTiger
about 25 days ago by StockTiger
Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); Facing Uphill Battle
May 03, 3:13PM Street Insider
May 03, 3:13PM Street Insider
Goldman Sachs Removes Onyx Pharmaceuticals (ONXX) from Conviction Buy List
May 03, 7:14AM Street Insider
May 03, 7:14AM Street Insider
Edwards Lifesciences, Panera Bread Among Stocks Up on High Volume Wednesday
Apr 25, 12:33PM Fox Business
Apr 25, 12:33PM Fox Business
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ONXX | 45.78 | -0.07 | -0.15% | 2.938B |
| ONVI | 3.93 | +0.07 | +1.81% | 32.77M |
| ONTY | 3.62 | +0.00 | +0.00% | 157.87M |
| ONSM | 0.5797 | -0.00 | -0.05% | 7.009M |
| ONP | 1.93 | -0.13 | -6.31% | 38.03M |
| ONNN | 6.76 | +0.00 | +0.00% | 3.056B |
| ONFC | 10.06 | +0.13 | +1.31% | 69.51M |
| ONEQ | 111.73 | -0.43 | -0.38% | |
| ONE | 12.75 | -1.43 | -10.08% | 805.57M |
| ONCY | 3.40 | -0.07 | -2.02% | 265.18M |